journavx vertex - Search News

Vertex Pharma Stock Surges

Bloomberg on MSN · 4h

New pain drug, Vertex’s Journavx, gets FDA approval as safer alternative to addictive opioids

Each year, about 125 million opioid prescriptions are written for Americans with pain caused by broken bones, burns, surgeries, and other injuries and procedures.

Seeking Alpha · 2h

Vertex Pharma Stock Surges After FDA Approves Non-Opioid Pain Drug

Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.

People on MSN · 2h

FDA Approves New Non-Opioid Painkiller, Journavx: 'No Addiction Potential'

One participant in the drug trial for Journavx said it eliminated her pain without making her feel loopy or nauseous, which she says she experienced when taking opioids.

AFP13h

Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...

6h

What's Happening With VRTX Stock?

With a rise in Trikafta demand, the investors have assigned a higher valuation multiple for VRTX stock. The increase in VRTX ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results